Diamantis I Tsilimigras, Odysseas P Chatzipanagiotou, Andrea Ruzzenente, Federico Aucejo, Hugo P Marques, Joao Bandovas, Tom Hugh, Nazim Bhimani, Shishir K Maithel, Minoru Kitago, Itaru Endo, Timothy M Pawlik
{"title":"Recurrence After Gallbladder Cancer Resection: Prognostic Impact of CA19-9 and CEA Levels at Baseline and During Surveillance.","authors":"Diamantis I Tsilimigras, Odysseas P Chatzipanagiotou, Andrea Ruzzenente, Federico Aucejo, Hugo P Marques, Joao Bandovas, Tom Hugh, Nazim Bhimani, Shishir K Maithel, Minoru Kitago, Itaru Endo, Timothy M Pawlik","doi":"10.1002/jso.70024","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Baseline serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) levels may predict prognosis among patients undergoing resection for gallbladder cancer (GBC), yet the prognostic utility of the combination of the two markers has not been well established. In addition, the prognostic significance of elevated preoperative CA19-9 levels that normalize after GBC resection is currently unknown.</p><p><strong>Methods: </strong>Patients undergoing resection of GBC between 2002 and 2021 were identified using an international, multi-institutional database. The association of preoperative CA19-9 and CEA levels with recurrence-free survival (RFS) following GBC resection was assessed. The negative predictive value (NPV) of normal vs. normalized (high preoperative/low postoperative levels) CA19-9 levels relative to the development of recurrence within 1 year after GBC resection was evaluated.</p><p><strong>Results: </strong>Among 194 patients who underwent resection of GBC, median preoperative CA19-9 and CEA levels were 18.8 U/mL (IQR 7.0-88.0) and 2.2 ng/mL (IQR 1.3-3.8), respectively. A total of 92 (47.4%) and 67 (34.5%) patients had elevated CA19-9 (> 20 U/mL) and CEA (> 3 ng/mL) levels before GBC resection, respectively. Individuals with low CA19-9/low CEA had the most favorable 3-year RFS (74.5%) after GBC resection followed by individuals with either high CA19-9 (high CA19-9/low CEA: 41.6%) or high CEA (low CA19-9/high CEA: 60.9%) levels, whereas patients with high CA19-9/high CEA had the worst 3-year RFS (21.5%) following GBC resection (p < 0.001). Patients with normal preoperative CA19-9 levels had better 3-year RFS than patients with high preoperative CA19-9 levels that normalized after resection (74.6% vs. 51.4%, p = 0.03). While the NPV of normal preoperative CA19-9 levels relative to the development of recurrence within 1 year after GBC resection was 94.7%, the NPV of normalized CA19-9 decreased to 70% at 1-year post-resection.</p><p><strong>Conclusion: </strong>Elevation of both preoperative CA19-9 and CEA levels portended poor prognosis following resection of GBC. Normalization of postoperative CA19-9 levels after GBC resection was still associated with elevated risk of recurrence. While preoperative tumor markers can accurately predict prognosis following resection for GBC, evaluation of traditional tumor markers may not be appropriate markers of occult recurrent disease in the postoperative setting. Better markers are needed to monitor for recurrence following resection of GBC.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.70024","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Baseline serum carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) levels may predict prognosis among patients undergoing resection for gallbladder cancer (GBC), yet the prognostic utility of the combination of the two markers has not been well established. In addition, the prognostic significance of elevated preoperative CA19-9 levels that normalize after GBC resection is currently unknown.
Methods: Patients undergoing resection of GBC between 2002 and 2021 were identified using an international, multi-institutional database. The association of preoperative CA19-9 and CEA levels with recurrence-free survival (RFS) following GBC resection was assessed. The negative predictive value (NPV) of normal vs. normalized (high preoperative/low postoperative levels) CA19-9 levels relative to the development of recurrence within 1 year after GBC resection was evaluated.
Results: Among 194 patients who underwent resection of GBC, median preoperative CA19-9 and CEA levels were 18.8 U/mL (IQR 7.0-88.0) and 2.2 ng/mL (IQR 1.3-3.8), respectively. A total of 92 (47.4%) and 67 (34.5%) patients had elevated CA19-9 (> 20 U/mL) and CEA (> 3 ng/mL) levels before GBC resection, respectively. Individuals with low CA19-9/low CEA had the most favorable 3-year RFS (74.5%) after GBC resection followed by individuals with either high CA19-9 (high CA19-9/low CEA: 41.6%) or high CEA (low CA19-9/high CEA: 60.9%) levels, whereas patients with high CA19-9/high CEA had the worst 3-year RFS (21.5%) following GBC resection (p < 0.001). Patients with normal preoperative CA19-9 levels had better 3-year RFS than patients with high preoperative CA19-9 levels that normalized after resection (74.6% vs. 51.4%, p = 0.03). While the NPV of normal preoperative CA19-9 levels relative to the development of recurrence within 1 year after GBC resection was 94.7%, the NPV of normalized CA19-9 decreased to 70% at 1-year post-resection.
Conclusion: Elevation of both preoperative CA19-9 and CEA levels portended poor prognosis following resection of GBC. Normalization of postoperative CA19-9 levels after GBC resection was still associated with elevated risk of recurrence. While preoperative tumor markers can accurately predict prognosis following resection for GBC, evaluation of traditional tumor markers may not be appropriate markers of occult recurrent disease in the postoperative setting. Better markers are needed to monitor for recurrence following resection of GBC.
期刊介绍:
The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.